The VDPHL01 hair loss trial has reported new 12-month results in men with pattern hair loss. On 9 November 2026, developer Veradermics announced continued gains with its experimental extended-release minoxidil tablets. The results come from a company statement, not a new peer-reviewed paper.
The VDPHL01 hair loss trial has reported new 12-month results in men with pattern hair loss. On 9 November 2026, developer Veradermics announced continued gains with its experimental extended-release minoxidil tablets. The results come from a company statement, not a new peer-reviewed paper.
What the VDPHL01 Hair Loss Trial Tested
Study 302 enrolled 519 men with mild to moderate pattern hair loss. Researchers assigned them to an 8.5 mg tablet once daily, the same dose twice daily, or placebo for six months.
After six months, the placebo group switched to active treatment. The new report covers the second six months of the study.
VDPHL01 uses a modified release system for minoxidil. Unlike topical minoxidil, patients swallow this formulation. However, VDPHL01 is not approved by the US FDA for hair loss.
What Changed at 12 Months
According to the company, men who stayed on twice-daily treatment gained an average of 43.9 non-vellus hairs per square centimetre from baseline. The once-daily group gained 29.7 hairs per square centimetre.
Non-vellus hairs are thicker, more visible hairs. Researchers count them in a marked scalp area to track change.
Meanwhile, 89.1% of the twice-daily group reported some visible improvement in coverage. The corresponding figure was 79.8% with once-daily dosing.
These are results within the treated groups at month 12. They are not a new 12-month comparison against placebo, because the placebo group crossed over to treatment after month six.
What We Know About Safety
Veradermics reported no new safety signals during the extension. It also reported no treatment-related serious adverse events and no cardiac adverse events of special interest in this study.
However, a study with hundreds of participants cannot rule out rare risks. Oral minoxidil affects the cardiovascular system. Therefore, any future approval will require close review of safety data, dosing and labelling.
The company has not yet published the full 12-month dataset in a peer-reviewed journal. Its press release also does not replace an independent regulatory assessment.
Why This Matters for Hair Restoration
Pattern hair loss affects many men and women. Patients may choose topical medicines, prescription treatments, surgery or combinations of these options.
A regulated oral formulation designed specifically for hair loss could add another choice if trials support approval. Yet the FDA has not approved VDPHL01, and patients should not confuse this experimental tablet with existing oral minoxidil use.
The VDPHL01 hair loss trial offers a useful signal about longer treatment. The next key step is full data review, including safety details and results from the broader trial programme.
Original source: https://veradermics.gcs-web.com/news-releases/news-release-details/veradermics-achieved-highest-vdphl01-reported-hair-count-phase-3 https://veradermics.gcs-web.com/news-releases/news-release-details/veradermics-achieved-highest-vdphl01-reported-hair-count-phase-3
This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.